Amna Nawaz
@PBSNewsHour·5.3M subscribers·62.2K videos
FDA criticized for working too closely with biotech company to approve Alzheimer's drug
Posted
December 30, 2022
Views
8,668
Likes
133
Engagement
1.53%
December 30, 2022
8,668
133
1.53%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
See what was published immediately before and after this episode.
5:58Now PlayingNew findings from a congressional investigation into the Food and Drug Administration and the biotech company Biogen find the FDA broke its own protocols to approve a new Alzheimer’s drug last year. The report said the FDA worked too closely with Biogen despite significant concerns over the limited benefits and side effects of the new drug, Aduhelm. Geoff Bennett reports.
Stream your PBS favorites with the PBS app
Find more from PBS NewsHour at
Subscribe to our YouTube channel
Subscribe:
PBS NewsHour podcasts
Newsletters
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
